BlinkLab (ASX:BB1) said the North Shore Pediatric Therapy joined its US clinical study, and it is expected to enroll patients in the coming weeks, according to a Monday Australian bourse filing.
As part of the US registrational study, North Shore's use of the ADOS-2 diagnostic tool will serve as a critical benchmark for standard-of-care comparisons, the filing said.
North Shore, a provider of pediatric services, specializing in the evaluation and treatment of autism, is the second US-based site to join the 100-patient initial phase of the registrational study.
The clinic also provides access to a diverse population of children throughout the Chicago area, ensuring the study reflects a broad range of backgrounds and developmental profiles.
The firm's shares rose 8% on market close on Monday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。